Alkermes (ALKS) EBT Growth (3y) (2013 - 2026)
Alkermes (ALKS) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 21.00% |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 1.19% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 3.60% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -29.91% |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 10.08% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 39.40% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.42 Bn | 397.90 Mn | -26.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.13% |
| Mar 31, 2026 | -76.13% |
| Dec 31, 2025 | -19.21% |
| Sep 30, 2025 | 51.76% |
| Jun 30, 2025 | 72.72% |
| Mar 31, 2025 | 36.91% |
| Dec 31, 2024 | 10.11% |
| Sep 30, 2024 | 83.25% |
| Jun 30, 2024 | 174.31% |
| Mar 31, 2024 | 65.28% |
| Dec 31, 2023 | 50.37% |
| Sep 30, 2023 | 248.41% |
| Jun 30, 2023 | 134.78% |
| Mar 31, 2023 | 28.74% |
| Dec 31, 2022 | 260.30% |
| Sep 30, 2022 | -7.74% |
| Jun 30, 2022 | 6.28% |
| Mar 31, 2022 | 23.43% |
| Dec 31, 2021 | 325.91% |
| Sep 30, 2021 | 7.78% |